Central administration of hypocretin-1 reverses narcolepsy in animal models [84, 85], but unfortunately the hypocretin peptide does not cross the blood brain barrier, thus a centrally penetrating agonist is needed to be usable. The gene discussed is HCRT; the disease is narcolepsy.